Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Crizotinib × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 43 Lung Neoplasms 10 Adenocarcinoma 3 Neoplasms 2 Carcinoma, Squamous Cell 2 ALK-positive NSCLC 2 Recurrence 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoma, Large-Cell, Anaplastic 1 Granuloma, Plasma Cell 1 Carcinoma, Large Cell 1 Carcinoma 1 Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer 1 Adenocarcinoma of Lung 1 ALK or ROS1-positive NSCLC 1

Interventions

Docetaxel 8 pembrolizumab 7 Pemetrexed 5 Carboplatin 5 Erlotinib Hydrochloride 4 toripalimab 3 Radiosurgery 3 Oxaliplatin 3 Nivolumab 3 Gemcitabine 3 Etoposide 3 Cisplatin 3 Bevacizumab 3 rociletinib 2 lorlatinib 2 fludarabine 2 atezolizumab 2 Vinorelbine 2 Topotecan 2 Radiotherapy 2 Platinum 2 Paclitaxel 2 Itraconazole 2 Irinotecan 2 Interleukin-2 2 Cyclophosphamide 2 Cetuximab 2 vinflunine 1 vandetanib 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown

Lung Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡